Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.

Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.

To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer.Vandetanib (an orally bioavailable VEGFR-2 and EGFR tyrosine kinases inhibitor) was combined at 100 mg, 200 mg, or 300...

Full description

Bibliographic Details
Main Authors: Jeffrey A Meyerhardt, Marek Ancukiewicz, Thomas A Abrams, Deborah Schrag, Peter C Enzinger, Jennifer A Chan, Matthew H Kulke, Brian M Wolpin, Michael Goldstein, Lawrence Blaszkowsky, Andrew X Zhu, Meaghan Elliott, Eileen Regan, Rakesh K Jain, Dan G Duda
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3373492?pdf=render

Internet

http://europepmc.org/articles/PMC3373492?pdf=render

Similar Items